Estamos realizando la búsqueda. Por favor, espere...
1578
37
170
28668
4379
2592
346
238
Abstract: This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.
Fuente: Lancet Oncol . 2021 Mar;22(3):e105-e118
Editorial: Lancet Pub. Group
Año de publicación: 2021
Nº de páginas: 14
Tipo de publicación: Artículo de Revista
DOI: 10.1016/S1470-2045(20)30756-7
ISSN: 1470-2045,1474-5488
Url de la publicación: https://www.doi.org/10.1016/S1470-2045(20)30756-7
Leer publicación
MOREAU, PHILIPPE
KUMAR, SHAJI K
SAN MIGUEL, JESÚS
DAVIES, FAITH
ZAMAGNI, ELENA
BAHLIS, NIZAR
LUDWIG, HEINZ
MIKHAEL, JOSEPH
TERPOS, EVANGELOS
SCHJESVOLD, FREDRIK
MARTIN, THOMAS
YONG, KWEE
DURIE, BRIAN G M
FACON, THIERRY
JURCZYSZYN, ARTUR
SIDANA, SURBHI
RAJE, NOOPUR
DONK, NIELS VAN DE
LONIAL, SAGAR
ENRIQUE MARIA OCIO SAN MIGUEL
Volver